Publications
Chad Thompson (162 POSTS)
2018 (9 POSTS)
Hexavalent chromium in drinking water
Moffat I, Martinova N, Seidel C, Thompson CM. 2018. Hexavalent chromium in drinking water. J AWWA 110(5):E22-E35; doi: 10.1002/awwa.1044.
View AbstractToxicity and recovery in the duodenum of B6C3F1 mice following treatment with intestinal carcinogens; captan, folpet, and hexavalent chromium: Evidence for an adverse outcome pathway
Thompson CM, Wolf JC, Suh M, Proctor DM, Haws LC, Harris MA. Toxicity and recovery in the duodenum of B6C3F1 mice following treatment with intestinal carcinogens; captan, folpet, and hexavalent chromium: Evidence for an adverse outcome pathway. Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.
View AbstractTen factors for considering the mode of action of Cr(VI)-induced intestinal tumors in rodents
Thompson CM, Suh M, Proctor DM, Harris MA. Ten factors for considering the mode of action of Cr(VI)-induced intestinal tumors in rodents. Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.
View AbstractAssessment of the mode of action underlying development of forestomach tumors in rodents following oral exposure to ethyl acrylate and relevance to humans
Thompson CT, Suh M, Chappell G, Borghoff S, Ellis-Hutchings, R, Wiench, K, Finch, L, Proctor DM. 2018. Assessment of the mode of action underlying development of forestomach tumors in rodents following oral exposure to ethyl acrylate and relevance to humans. Regul Toxicol Pharmacol 96:178–189; doi: 10.1016/j.yrtph.2018.05.006.
View AbstractA review of the genotoxic, mutagenic, and carcinogenic potentials of several lower acrylates
Suh M, Proctor DM, Chappell G, Rager JE, Thompson CM, Borghoff S, Finch L, Ellis-Hutchings R, Wiench K. 2018. A review of the genotoxic, mutagenic, and carcinogenic potentials of several lower acrylates. Toxicol 402-403(June 1):50-67; doi: 10.1016/j.tox.2018.04.006.
View AbstractAn adverse outcome pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events
Proctor DM, Suh M, Chappell G, Borghoff SJ, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. 2018. An adverse outcome pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regul Toxicol Pharmacol, 96(July):30-40; doi: 10.1016/j.yrtph.2018.04.016.
View AbstractIntegration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium
Thompson CM, Kirman CR, Hays SM, Suh M, Harvey SE, Proctor DM, Rager JE, Haws LC, Harris MA. 2018. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. J Appl Toxicol 38:351–365. doi: 10.1002/jat.3545.
View Abstract2017 (10 POSTS)
Benchmark dose modeling estimates of the concentrations of inorganic arsenic that induce changes to the neonatal transcriptome, proteome, and epigenome in a pregnancy cohort
Rager JE, Auerbach SS, Chappell GA, Martin E, Thompson C, Fry RC. 2017. Benchmark dose modeling estimates of the concentrations of inorganic arsenic that induce changes to the neonatal transcriptome, proteome, and epigenome in a pregnancy cohort. Chem Res Toxicol 30(10):1911-1920; doi: 10.1021/acs.chemrestox.7b00221.
View AbstractTen factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents
Thompson CM, Suh M, Proctor DM, Haws LC, Harris MA. 2017. Ten factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents. Mutat Res 823(Nov):45-57; doi: 10.1016/j.mrgentox.2017.08.004.
View AbstractAssessment of the mutagenic potential of hexavalent chromium in the duodenum of Big Blue® rats
Thompson CM, Young RR, Dinesdurage H, Suh M, Harris MA, Rohr AC, Proctor DM. 2017. Assessment of the mutagenic potential of hexavalent chromium in the duodenum of Big Blue® rats. Toxicol Appl Pharmacol 330(1):48-52; 10.1016/j.taap.2017.07.002.
View AbstractHigh-throughput screening data interpretation in the context of in vivo transcriptomic responses to oral Cr(VI) exposure
Rager JE, Ring CL, Fry RC, Suh M, Proctor DM, Haws L, Harris MA, Thompson CM. 2017. High-throughput screening data interpretation in the context of in vivo transcriptomic responses to oral Cr(VI) exposure. Toxicol Sci 158(1):199–212; doi: 10.1093/toxsci/kfx085.
View AbstractA proposed ADI for nitrate
Doepker D, Tyndall K, Lane R, Wikoff D, Thompson C, Harvey S, Schmitt D. 2017. A proposed ADI for nitrate. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.
View AbstractMechanistic support for nonlinear risk assessment of rat oral cavity tumors induced by exposure to Cr(VI) in drinking water
Thompson C, Rager J, Suh M, Proctor D, Haws L, Harris M. Mechanistic support for nonlinear risk assessment of rat oral cavity tumors induced by exposure to Cr(VI) in drinking water. Poster presented at 56th Society of Toxicology Annual Meeting. March 15, Baltimore, MD, March 2017.
View AbstractUsing physiologically-based pharmacokinetic modeling to address potentially sensitive subpopulations exposure to hexavalent chromium
Kirman CR, Proctor D, Suh M, Haws L, Harris M, Thompson C, Hays S. Using physiologically based pharmacokinetic modeling to address potentially sensitive subpopulations exposed to hexavalent chromium. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.
View AbstractIntegration of transcriptomics and high-throughput screening predictions with robust in vivo data to inform hexavalent chromium mode of action
Rager JE, Thompson CM, Ring C, Fry RC, Harris MA. Integration of transcriptomics and high-throughput screening predictions with robust in vivo data to inform hexavalent chromium mode of action. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.
View AbstractRisk assessment of oral exposure to Cr(VI): Integration of mode of action, pharmacokinetics, and dose-response modeling
Thompson C, Kirman C, Suh M, Proctor D, Haws L, Harris M, Hays S. 2017. Risk assessment of oral exposure to Cr(VI): Integration of mode of action, pharmacokinetics, and dose-response modeling. Poster presented at Society of Toxicology Annual Meeting, March 14, Baltimore, MD.
View AbstractComparison of toxicity and recovery in the duodenum of B6C3F1 mice following treatment with intestinal carcinogens captan, folpet, and hexavalent chromium
Thompson CM, Wolf, JC, McCoy A, Suh M, Proctor DM, Kirman CR, Haws LC, Harris MA. 2017. Comparison of toxicity and recovery in the duodenum of B6C3F1 mice following treatment with intestinal carcinogens captan, folpet, and hexavalent chromium. Toxicol Pathol 45(8):1091–1101; doi: 10.1177/019262331yy4324.
View Abstract2016 (10 POSTS)
Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium
Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801(April):28-34; doi: 10.1016/j.mrgentox.2016.01.008.
View AbstractTranscriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment
Thompson CM, Rager JE, Suh M, Ring CL, Proctor DM, Haws LC, Fry RC, Harris MA. 2016. Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment. Environ Molec Mutagen 57(9):706-716; doi: 10.1002/em.22064.
View AbstractIntegrating genomic and epigenomic data into risk assessment applications through dose response modeling: Case study with prenatal arsenic exposure
Rager J, Thompson C, Auerbach S, Fry R. Integrating genomic and epigenomic data into risk assessment applications through dose response modeling: Case study with prenatal arsenic exposure. Environmental Mutagenesis and Genomics Society, Kansas City, KS, September 2016.
View Abstract